MEETING REPORT - 54th ICAAC

Washington DC

12/09/2014 - ICAAC 2014 had limited news on antifungal drug-drug interactions. Most news was on the new agent Isavuconazole.

This year at ICAAC limited data were presented on drug-drug interactions with antifungal drugs. All available abstracts on drug-interactions are listed.

Abstract A-695: Dr. Yamazaki presented data on an open-label, two-arm, Phase 1 study in healthy subjects aged 18-55 years of isavuconazole with ketoconazole. They concluded that multiple doses of ketoconazole increased the exposure to isavuconazole ~5.2-fold. According to the authors, co-administration of ketoconazole with single dose isavuconazole was well tolerated in this study; single dose isavuconazole was also well tolerated.

Abstract A-696: Dr. Desai presented an open-label, two-arm, Phase 1 drug-drug interactions study on Isavuconazole with caffeine and repaglinide study in healthy subjects aged 18-55 years. The authors concluded that multiple doses of isavuconazole decreased the exposure to repaglinide by 8% and increased the exposure to caffeine by 4%. In this study co-administration of isavuconazole with repaglinide or with caffeine was well-tolerated.

RECENT NEWS | ARCHIVE